Cargando…

COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies

BACKGROUND: Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to understand the impact of COVID-19 on new and pre-existing symptoms of MS. METHODS: The COVID-19 and MS study is an ong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garjani, Afagh, Middleton, Rodden M, Hunter, Rachael, Tuite-Dalton, Katherine A, Coles, Alasdair, Dobson, Ruth, Duddy, Martin, Hughes, Stella, Pearson, Owen R, Rog, David, Tallantyre, Emma C, das Nair, Roshan, Nicholas, Richard, Evangelou, Nikos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585399/ https://www.ncbi.nlm.nih.gov/pubmed/34010764 http://dx.doi.org/10.1016/j.msard.2021.102939

Ejemplares similares

Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register
por: Evangelou, Nikos, et al.
Publicado: (2021)

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study
por: das Nair, Roshan, et al.
Publicado: (2021)

Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
por: Garjani, Afagh, et al.
Publicado: (2021)

Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Garjani, Afagh, et al.
Publicado: (2022)

Decentralised clinical trials in multiple sclerosis research
por: Garjani, Afagh, et al.
Publicado: (2022)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey
por: Huang, Yun, et al.
Publicado: (2021)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

The impact of smoking cessation on multiple sclerosis disease progression
por: Rodgers, Jeff, et al.
Publicado: (2021)

Self-help Acceptance and Commitment Therapy for Carers of People with Multiple Sclerosis: A Feasibility Randomised Controlled Trial
por: Potter, Kristy-Jane, et al.
Publicado: (2020)

Developing a patient care pathway for emotional support around the point of multiple sclerosis diagnosis: A stakeholder engagement study
por: Tindall, Tierney, et al.
Publicado: (2023)

Newer therapies for multiple sclerosis
por: Coles, Alasdair
Publicado: (2015)

Association Between Platelet Count as a Noninvasive Marker and Ultrasonographic Grading in Patients With Nonalcoholic Fatty Liver Disease
por: Garjani, Afagh, et al.
Publicado: (2015)

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial
por: Topcu, Gogem, et al.
Publicado: (2022)

Promoting remyelination in multiple sclerosis
por: Cunniffe, Nick, et al.
Publicado: (2019)

Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies
por: Topcu, Gogem, et al.
Publicado: (2022)

Dorsolateral prefrontal circuit effective connectivity mediates the relationship between white matter structure and PASAT‐3 performance in multiple sclerosis
por: Meng, Dewen, et al.
Publicado: (2020)

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
por: Allen-Philbey, Kimberley, et al.
Publicado: (2020)

A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test
por: Middleton, Rod M, et al.
Publicado: (2020)

Early depressive symptoms and disability accrual in Multiple Sclerosis: a UK MS Register study
por: Jacobs, Benjamin M., et al.
Publicado: (2023)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Developing a clinical pathway to identify and manage cognitive problems in Multiple Sclerosis: Qualitative findings from patients, family members, charity volunteers, clinicians and healthcare commissioners
por: Smith, Laura, et al.
Publicado: (2021)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Early MRI predictors of prognosis in multiple sclerosis
por: Davda, Nikunj, et al.
Publicado: (2019)

Usability and acceptability of a cognitive training intervention (SMART) for people with multiple sclerosis (MS): A prefeasibility formative evaluation
por: Frost, Alexandra C., et al.
Publicado: (2022)

Physical Disability, Anxiety and Depression in People with MS: An Internet-Based Survey via the UK MS Register
por: Jones, Kerina H., et al.
Publicado: (2014)

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study
por: Papathanasiou, Athanasios, et al.
Publicado: (2023)

Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial
por: Golijani-Moghaddam, Nima, et al.
Publicado: (2022)

How to run a multiple sclerosis relapse clinic
por: Tallantyre, Emma C, et al.
Publicado: (2016)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
por: Tallantyre, Emma C, et al.
Publicado: (2022)

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
por: Jacobs, Benjamin M, et al.
Publicado: (2023)

Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study
por: Nicholas, Richard S, et al.
Publicado: (2020)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Trial protocol: Feasibility of neuromodulation with connectivity-guided intermittent theta-burst stimulation for improving cognition in multiple sclerosis
por: Blanchard, Caroline, et al.
Publicado: (2023)

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2021)

The factor structure of the Center for Epidemiological Study - Depression Scale in people with multiple sclerosis
por: Kneebone, Ian I., et al.
Publicado: (2020)

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
por: Palace, Jacqueline, et al.
Publicado: (2014)

Driving ability and predictors for driving performance in Multiple Sclerosis: A systematic review
por: Seddiq Zai, Susan, et al.
Publicado: (2022)

COVID‐19 Vaccine Response in People with Multiple Sclerosis
por: Tallantyre, Emma C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ohv08a8q7pau2tcor7h78dkn5p